Sort   by:  
 Page size 
MetabolomicsNanoinducers-mediated Mitochondria-Selective Degradation Enhance T Cell Immunotherapy Against Multiple Cancers

Cancer immunotherapy utilizing cytotoxic T lymphocytes (CTLs) has demonstrated significant promise in clinical applications, but cancer immunosuppressive mechanisms hamper further progress in T cell immunotherapy. Here we show a correlation between cancer cell mitochondria content and their resis...

2025-03-13 | MTBLS12284 | MetaboLights
MetabolomicsMicrobial Product Cocktails for Personalized Cancer Immunotherapy

The human immune system has evolved to interact with various commensal and pathogenic bacteria in intricate and nuanced ways. While the diversity of bacteria presents fundamental challenges in understanding immune-microbe interactions, it also offers ample opportunities for developing effective i...

2025-07-01 | MTBLS12666 | MetaboLights
MetabolomicsCirculating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer

The effectiveness of immunotherapy varies among patients with advanced non-small cell lung cancer (NSCLC). Here we investigated the baseline immune status in stage IV NSCLC patients treated with anti-PD-1 plus chemotherapy to understand the immune mechanisms and unveil systemic markers associated...

2025-10-16 | MTBLS13150 | MetaboLights
MetabolomicsIn Vivo CRISPR Screens Identify SLC1A5 as a Metabolic Barrier for Cancer Immunotherapy
Tumor metabolic reprogramming profoundly shapes antitumor immunity, but the mechanisms linking glutamine metabolism to immune evasion in hepatocellular carcinoma (HCC) remain incompletely understood. Here, we identify the glutamine transporter SLC1A5 as a tumor-intrinsic regulator of HCC progression...
2026-08-20 | MTBLS15401 | MetaboLights
MetabolomicsFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights
MetabolomicsActivated ATF6α is a hepatic tumor driver restricting immunosurveillance

Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related mortality with limited therapies. While endoplasmic reticulum (ER)-stress and the unfolded protein response (UPR) are implicated in HCC, the involvement of the UPR-transducer activating transcription factor 6 alpha (ATF...

2025-11-17 | MTBLS13241 | MetaboLights
MetabolomicsLow-Protein Diet Enhances Anti-Tumor Immunity in Pancreatic Cancer through Microbiota-Derived Uridine Diphosphate-Galactose
Low-protein diets (LPD) have been linked to improved metabolic health, but their role in pancreatic ductal adenocarcinoma (PDAC) immunotherapy remains unclear. Here we show that an LPD suppresses PDAC progression in male mice by remodeling the gut microbiota and activating anti-tumor immunity. LPD p...
2026-07-09 | MTBLS14989 | MetaboLights
MetabolomicsCaffeine Enhances Antitumor T-cell Activity via COL12A1/IDO1/Kyn axis and Sensitivity to Anti-PD-1 Immunotherapy in Colorectal Cancer
Metabolomic sequencing on supernatants from caffeine-treated and untreated tumor cells to identify which metabolites are involved in activating CD8+ T cells
2025-05-06 | MTBLS11623 | MetaboLights
TranscriptomicsIL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
IL-2 and IL-21 are closely related cytokines that might have arisen by gene duplication. Both cytokines promote the function of effector CD8+ T cells, but their distinct effects on antigen-driven differentiation of naïve CD8+ T cells into effector CD8+ T cells are not clearly understood. We found t...
ORGANISM(S): Mus musculus 
2010-05-26 | E-GEOD-10403 | biostudies-arrayexpress
TranscriptomicsTumor-specific CD4+ T cells eradicate established melanoma
Adoptive transfer of CD4+ T cells (TRP-1 CD4+ T cells) specific for tyrp-1 (tyrosinase-related protein 1) eradicate established tumors (melanoma) in lymphopenic RAG-/- hosts. In vitro differentiated CD8+ T cells have been the primary focus of immunotherapy of cancer with little focus on CD4+ T cells...
ORGANISM(S): Mus musculus 
2010-01-14 | E-GEOD-19904 | biostudies-arrayexpress
Sort   by:  
 Page size